Last updated: July 27, 2026
What is the Beckman Coulter v. Cytek Biosciences patent and technology litigation about (1:24-cv-00945)?
Summary: The available record for Beckman Coulter, Inc. v. Cytek Biosciences, Inc., 1:24-cv-00945 is not provided in the prompt. Without the complaint, asserted claims, exhibit list, court filings, or docket events, a complete and accurate litigation summary cannot be produced.
What patents are asserted in Beckman Coulter Inc. v. Cytek Biosciences Inc. (1:24-cv-00945)?
Summary: The specific asserted patents, patent numbers, priority dates, claim scope (independent vs dependent), and whether the suit targets detector hardware, spectral unmixing software, analysis algorithms, or calibration methods are not included in the prompt.
Which Beckman patents are listed, and what claim elements do they cover?
No asserted-patent identifiers or claim charts are available in the provided information.
Are software, method claims, or system claims asserted?
No claim-type information is available in the provided information.
What is the procedural posture of the Beckman v. Cytek case (1:24-cv-00945)?
Summary: The current procedural status (e.g., complaint filed, TRO request, motion to dismiss, claim construction, infringement contentions, invalidity contentions, Markman, summary judgment, trial scheduling) is not included.
Key docket milestones and deadlines
No docket events or dates are provided.
Has there been a Markman order, amended complaint, or stipulations?
No case documents are provided.
What is being alleged: infringement theory, willfulness, and damages in Beckman v. Cytek (1:24-cv-00945)?
Summary: Without the complaint, allegations of direct infringement, induced infringement, contributory infringement, and willfulness cannot be stated.
Are the allegations directed to flow cytometry optics, fluorescence detection, spectral compensation, or unmixing?
The underlying technology and theory are not provided.
What damages model is claimed (lost profits, reasonable royalty, enhanced damages)?
No damages theory is included in the prompt.
What defenses does Cytek raise in Beckman v. Cytek (1:24-cv-00945)?
Summary: The defenses and counterclaims cannot be identified without the answer, motions to dismiss, or invalidity filings.
What invalidity arguments are made (anticipation/obviousness, written description, indefiniteness, enablement)?
No invalidity content is provided.
Any noninfringement positions (claim construction dependent or design-around)
No noninfringement arguments are provided.
What motions matter in Beckman v. Cytek (1:24-cv-00945): dismissal, claim construction, preliminary injunction?
Summary: Motion practice (PI/TRO, dismissal, stay requests, consolidation, protective orders) is not provided.
Has Beckman sought a preliminary injunction or temporary restraining order?
No motion details are included.
Has the court set claim construction (Markman) for specific terms?
No Markman or scheduling information is included.
How strong is Beckman’s asserted patent estate versus Cytek’s risk (1:24-cv-00945)?
Summary: A strength analysis requires the asserted patents, claim scope, prosecution history, claim limitations tied to accused products, and prior art references. None are provided.
What prior art is likely implicated and how does it map to the asserted claims?
No asserted-claim limitations or prior art references are provided.
How vulnerable are the asserted patents to invalidity challenges?
No patent data or litigation positions are provided.
What products are allegedly accused by Cytek in this case?
Summary: Accused products (model names, software versions, instrument configurations, or detector/calibration subsystems) are not included.
Which Cytek systems or software features are at issue (by name)?
No product identifiers are provided.
How does Beckman allege the accused products meet each asserted claim element?
No infringement chart or element-by-element mapping is available in the prompt.
Is there any settlement or licensing agreement connected to Beckman v. Cytek (1:24-cv-00945)?
Summary: Settlement or licensing terms are not provided.
Did the parties file joint stipulations or dismissals?
No docket or order text is provided.
Any public statements about cross-licenses or supply/royalty arrangements
No statements are included.
What is the litigation exposure for Cytek and Beckman under damages and injunctive relief scenarios?
Summary: Quantification requires (1) accused sales and margins, (2) royalty benchmarks, (3) evidence of market substitution, (4) willfulness findings, and (5) any injunctive relief likelihood. None are provided.
Commercial exposure
No revenue or product penetration figures are included.
Injunction risk
No preliminary injunction record is provided.
Key Takeaways
No complete, accurate litigation summary or analysis can be generated from the information provided.
